Navigation Links
Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
Date:9/19/2011

NEW YORK, Sept. 19, 2011 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) announced today that management will present at the JMP Securities Healthcare Conference on Wednesday, September 28, 2011 at 11:00 A.M. ET in New York, NY.  David McDonald, Chief Financial Officer, will provide an overview of the Company's business strategy and recent corporate developments.

Attendance at this conference is by invitation only.  Delcath will offer a live webcast and subsequent archived replay of its presentation, which may be accessed at http://www.delcath.com/investors/events/.

About Delcath SystemsDelcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company's website at http://www.delcath.com/.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to di
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 18, 2014   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization ... positive results from its pivotal field study of ... pain in dogs with osteoarthritis.  In the study, ... scores that were statistically significant compared to placebo ...
(Date:12/17/2014)... Revenue and earnings above the previous year - ... In the past 2013/14 fiscal year (ended 30 September ... 4.287 billion (last year: EUR 4.190 billion) despite unfavorable currency ... million. "Overall, 2013/14 was a successful fiscal year for the ... CEO of Carl Zeiss AG. "Thanks to our broad portfolio ...
(Date:12/17/2014)... 2014 , The ... hub of information concerning the biopharmaceutical Group,s national and international ... addition to the recently launched institutional website that is receiving ... enriched by a new chapter in the fascinating story of ... detailed and panoramic hub on the world of clinical research, ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
... 2011 CVS Caremark Corporation (NYSE: CVS ... Executive Officer, will be making a presentation to investors ... June 1, 2011. Mr. Merlo is scheduled to present ... An audio webcast of the presentation will be ...
... U.S. Food and Drug Administration today approved Edurant (rilpivirine) ... of HIV-1 infection in adults who have never taken ... ) Edurant belongs to a class ... The drug works by blocking HIV viral replication. Edurant ...
Cached Medicine Technology:FDA Approves New HIV Treatment 2FDA Approves New HIV Treatment 3
(Date:12/21/2014)... As testosterone therapy lawsuit filings on ... clots from using testosterone products such as AndroGel and ... the male hormone testosterone may increase the risk of ... the Proceedings of the National Academy of Sciences in ... male rats with naturally occurring colon cancer. Dr. Amos-Landgraf, ...
(Date:12/20/2014)... BambooIndustry.com is a professional company offering ... has recently shown its new engineered bamboo flooring collection, ... flooring models. , BambooIndustry.com’s customers come from many countries ... According to the CEO of the company, the global ... the past few years, and the demand for eco-friendly ...
(Date:12/20/2014)... An improving macroeconomic landscape and a ... Massage Services industry over the five years ... the anticipated 1.0% annualized increase in per capita disposable ... the means to afford additional massages. “While the share ... a given year has declined from 2009 to 2012, ...
(Date:12/20/2014)... 2014 (HealthDay News) -- The holidays can be anything ... with fresh trees, scented candles and other allergy triggers. ... decorations that have been packed away in dank basements ... and asthma patients," Dr. Rachna Shah, an affiliate faculty ... said in Loyola news release. Shah, who is ...
(Date:12/20/2014)... December 20, 2014 As Risperdal ... forward in U.S. courts, Bernstein Liebhard LLP notes ... that children treated with the medication may experience ... breast development and lactation. The study, which appears ... and adolescents who began treatment with risperidone, an ...
Breaking Medicine News(10 mins):Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 2Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 3Health News:New Low Testosterone Therapy Study Shows Male Hormone Testosterone May Contribute To Colon Cancer Reports Wright & Schulte LLC 4Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Holiday Trimmings Can Trigger Allergies 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4
... study of young U.S. teens showed that between 11 ... an alcohol brand, and those who do appear more ... susceptibility, to beginning drinking, to binge drinking, according to ... of Pediatrics & Adolescent Medicine . , Alcohol-branded merchandise ...
... (Nasdaq: AIRM ) will report financial results for ... of the market on Tuesday, March 10, 2009. The ... 2009 at 4:15 p.m. Eastern to discuss these results. ... (domestic) or (706) 643-8826 (international) or by accessing the web ...
... surgery can restore function for obese males, study finds , , ... man, the greater his hormonal changes and the worse his ... side, the study,s authors found that gastric bypass surgery can ... obesity is correlated to lower sperm count and can be ...
... is best bet, experts say , , TUESDAY, March 3 ... find new solutions to combat the growing resistance to ... , "The startling news about oseltamivir [Tamiflu] resistance should ... effort to cope with this rapidly evolving pathogen," wrote ...
... second overall and first for long-term investment and social ... Diagnostics Incorporated (NYSE: DGX ), the world,s ... again been named to FORTUNE magazine,s list of the ... the "Health Care" category of "Pharmacy and Other Services." ...
... and CEO of the New Canadian EntityWHIPPANY, N.J., March ... company, has announced today that it is establishing a ... Ltd. This company will have its headquarters in Ontario, ... sale and distribution of branded pharmaceutical products currently available ...
Cached Medicine News:Health News:Owning alcohol-branded merchandise associated with teen drinking behaviors 2Health News:Men's Sex Lives May Suffer as Waistlines Expand 2Health News:Concerted Effort Needed to Fight Drug-Resistant Flu Strain 2Health News:Concerted Effort Needed to Fight Drug-Resistant Flu Strain 3Health News:Quest Diagnostics Again Named to FORTUNE Magazine's 'World's Most Admired Companies' List 2Health News:Halo Pharmaceutical Launches a Branded Product Marketing Company in Canada 2
Large....
These products are supplied non-sterile and must be sterilized before use. For insertion through the smokevac and nezhat-dorsey trumpet valve in conjunction with the universal instrument insert adapt...
... Utilizing breakthrough electro-optical and rotary ... SUPRA is capable of obtaining ... pupils as narrow as 2.0mm. ... precise diagnostic results when dealing ...
Sterile perfluorocarbon for intraocular Application....
Medicine Products: